Multiple myeloma trials

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants is being studied. Conditions: Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection • Eligibility: * INCLUSION CRITERIA-TRANSPLANT RECIPIENTS: Patients surviving three years or more from date of first stem cell transplant who have been treated. -With an experimental allogeneic stem cell transplant…. Goal: This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Heart, Lung, and Blood Institute (NHLBI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The MYRIAM project tests a nationwide registry in Germany to collect information about multiple myeloma patients, including how they’re diagnosed and treated, and also gathers patient-reported outcomes, over up to five years. - It aims to learn real-world treatment patterns and outcomes and to build a decentralized biobank. - It is for adults with multiple myeloma who need systemic therapy; recruitment is currently open for third-line and later lines (first- and second-line recruitment are closed), and participants must consent in German. - Exclusions include people not receiving systemic therapy and those already enrolled in studies that prohibit participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether ide-cel (bb2121) CAR T-cell therapy for multiple myeloma can be made from a patient’s T cells after a hematopoietic cell transplant, and whether the quality of those T cells affects how well ide-cel prevents the cancer from returning. - It includes two groups of adults with relapsed or refractory multiple myeloma who have had at least four prior therapies and a transplant: Cohort 1 is autoHCT within 2–6 months, Cohort 2 is after alloHCT with minimal residual disease. - The trial aims to learn if the cell source and manufacturing quality influence ide-cel’s effectiveness and safety after transplantation. - The study is currently recruiting. - Key exclusions include active infection, significant organ dysfunction, prior organ transplant requiring systemic immunosuppression, and pregnancy or breastfeeding, among other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests whether iberdomide maintenance is better or similar to lenalidomide maintenance after autologous stem cell transplantation in people with newly diagnosed multiple myeloma. - It is for adults with symptomatic multiple myeloma who have completed induction therapy that included a proteasome inhibitor and an IMiD, and who have had one or two autologous stem cell transplants within 12 months (single) or 15 months (tandem) from the start of induction, achieving at least a partial response. - The trial aims to learn which maintenance approach helps keep the cancer under control after transplant and how tolerable the treatments are. - Key exclusions include progressive disease after transplant, smoldering or nonsecretory myeloma, CNS involvement, and a prior history of other cancers unless disease-free for at least 5 years.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial is testing linvoseltamab (REGN5458) against the three-drug combination EPd (elotuzumab, pomalidomide, dexamethasone) in adults with relapsed or refractory multiple myeloma. - Eligible participants are adults with measurable disease who have had 1 to 4 prior myeloma therapies (including lenalidomide and a proteasome inhibitor) and good organ function, and they will be randomly assigned to receive either linvoseltamab or EPd. - The study aims to learn how safe and effective linvoseltamab is compared with EPd, including how long benefits last, response rates, overall survival, and effects on pain. - Key exclusions include prior treatment with elotuzumab or pomalidomide, brain lesions or PML, active serious infections, recent stem cell transplant, and certain infections like HIV, HBV, or HCV.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests 11 selinexor-based combination treatments with dexamethasone for adults with multiple myeloma, including both relapsed/refractory and newly diagnosed patients. - It uses a dose-escalation and expansion design to find safe dose levels and to learn how effective and safe the regimens are. - Eligibility includes adults with measurable myeloma and adequate organ function; key exclusions include non-secretory myeloma, active hepatitis B/C or HIV, pregnancy, significant heart problems, prior SINE exposure, and other treatment-related exclusions. - Most arms have completed enrollment, while Arm 12 (mezigdomide-containing regimen) is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a drug called JNJ-79635322 to see if it helps people with relapsed or refractory multiple myeloma. It is for adults who have had at least three prior therapies, including a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody, and who have measurable disease. Researchers want to learn how well the drug works and how safe it is in this group. Key exclusions include allergies to the drug’s ingredients, major surgery within two weeks before dosing, active CNS involvement or leptomeningeal disease, and a second cancer that could interfere with results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- A new PET imaging probe called 68Ga-NB381 that targets CD38 is being tested for multiple myeloma. - The study is for adults with suspected multiple myeloma who are about to have a bone marrow biopsy, or adults with confirmed symptomatic MM. - Researchers will compare 68Ga-NB381 PET/CT with the standard 18F-FDG PET imaging to see how accurate, specific, and safe it is for MM diagnosis. - The trial aims to help tailor treatment plans based on CD38 expression and to monitor responses to CD38-targeted therapies like daratumumab. - Exclusions include pregnant women and anyone who cannot understand or cooperate with the exam.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic trial tests adding venetoclax to three standard myeloma regimens—Rd (lenalidomide+dexamethasone), Dd (daratumumab+dexamethasone), and DRd (daratumumab+lenalidomide+dexamethasone)—in adults with multiple myeloma, focusing on the t(11;14) abnormality. It uses a dose-escalation design to find the recommended phase II dose of venetoclax and to assess safety, side effects, and how well the treatment works. The study has two groups: relapsed myeloma (Group 1) and newly diagnosed myeloma (Group 2), with assignment to the different arms accordingly. Eligibility requires measurable disease and adequate organ function; key exclusions include recent other cancers (with some exceptions), HIV, certain drug interactions (CYP3A inhibitors/inducers), major GI issues, recent major surgery, and pregnancy risk with lenalidomide-containing therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1 rolling-6 study testing a new BCMA CAR-T therapy alone and a BCMA/CD19 CAR-T therapy in adults with relapsed or refractory multiple myeloma. It aims to evaluate the safety and feasibility of manufacturing these CAR-T cell products and administering them to patients. Eligible participants are adults (18+) with relapsed/refractory multiple myeloma after at least 3 prior therapies who are refractory to their last treatment. Key exclusions include prior gene or cell therapy, active infection, and significant cardiovascular or liver disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies is being studied. Conditions: Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia +3 • Eligibility: Inclusion Criteria: * Age 18 years or older * Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary…. Goal: This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory and thinking in patients with blood cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Detection and Screening of Hematological Malignancies - SANGUINE is being studied. Conditions: Hematologic Malignancy • Eligibility: Inclusion Criteria: General criteria for all study populations: 1. Male and female subjects ≥18 years of age 2. Ability to understand and willingness to sign a written informed…. Goal: This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions \[smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)\], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)\*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease. \*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included Phase/Status/Sponsor: Unknown phase; RECRUITING; JaxBio Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies is being studied. Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse +3 • Eligibility: Inclusion Criteria: 1. Histologically confirmed diagnosis of CD19+ ALL, CD19+ NHL, or BCMA+ MM per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (2020.v2); 2. Relapsed…. Goal: A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zhejiang University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests an experimental drug called linvoseltamab in adults with AL amyloidosis whose disease has returned or progressed after prior treatment, and it is currently recruiting. It has two parts: Phase 1 looks at safety and helps find the right dose, and Phase 2 expands to see if the drug works and remains safe in more participants. Researchers want to know if linvoseltamab can lower abnormal light-chain proteins and improve heart or kidney problems, plus how much drug is in the blood and whether the body makes antibodies against it. Key exclusions include having another type of amyloidosis, very high bone marrow plasmacytosis or bone lesions, a recent heart attack, or an active infection requiring hospitalization or IV antibiotics near the start.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a Phase 1b, open-label trial testing OPN-6602, given alone or with dexamethasone, in people with relapsed or refractory multiple myeloma. - It aims to assess safety and tolerability, how the drug behaves in the body, and any early signs of anti-tumor activity. - Eligible participants have confirmed multiple myeloma that has relapsed or progressed after at least three prior lines of therapy (including IMiDs, proteasome inhibitors, and anti-CD38 therapy) and must have adequate organ function. - Key exclusions include MGUS or smoldering myeloma, active plasma cell leukemia, POEMS syndrome, recent stem cell transplant, active infection, poorly controlled Type 2 diabetes, and other active cancers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether combining PET imaging with bone marrow testing, whole exome sequencing, and next-generation flow cytometry can better measure minimal residual disease and predict how long patients stay free of disease in newly diagnosed multiple myeloma. It is for adults who are transplant-eligible and start standard care with induction chemotherapy, autologous stem cell transplant, and lenalidomide maintenance. The study aims to identify diagnostic features and risk factors for early relapse to support more personalized treatment in the future. Only patients who reach very good partial response after induction and transplant will have repeat PET/CT scans and MRD testing; others will have maintenance follow-up, and key exclusions include claustrophobia or inability to lie still, uncontrolled diabetes, pregnancy, active other cancers (with exceptions), or inability to consent.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring is being studied. Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma +2 • Eligibility: Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants…. Goal: The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Carevive Systems, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a multicenter retrospective and prospective observational study of adults with relapsed and refractory multiple myeloma who have previously received anti-CD38 monoclonal antibodies and immunomodulatory drugs and are treated with on-label regimens. - The trial aims to learn real-world treatment patterns and outcomes in this patient group. - Eligible participants are adults (18+) who can consent to the review of their clinical data; there are two tracks (Phase I and Phase II) based on prior therapy and the on-label treatment scheme. - Exclusion: those not willing to consent to the review of their clinical data; the study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests belantamab mafodotin in combination with daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma who are transplant-ineligible. - It is a phase 1/2, open-label trial designed to assess safety and clinical activity and to determine the recommended phase 2 dose for future study. - About 36 participants will be enrolled, with follow-up of up to 3 years after the last participant is randomized. - Key exclusions include prior systemic therapy for multiple myeloma and significant organ dysfunction or active infections, among other criteria.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma is being studied. Conditions: Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma +5 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Non Hodgkin or Hodgkin lymphoma or histiocytic/dendritic cell neoplasm meeting one of the following criteria: * Biopsy-proven relapsed and/or refractory…. Goal: This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their cancer (refractory) or for patients with histiocytic/dendritic cell neoplasm. Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an electrocardiogram (ECG)…. Goal: This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion. GSK2636771 may block a protein called PI3K-beta, which may be needed for growth of cancer cells that express PTEN mutations. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CAR- PRISM (PRecision Intervention Smoldering Myeloma) is being studied. Conditions: Multiple Myeloma, Smoldering Multiple Myeloma • Eligibility: Inclusion Criteria: * Age \> 18 years. * High-risk SMM with ≤40% plasma cells in the bone marrow and with high-risk criteria defined as having 1 of the…. Goal: The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: * Cilta-cel (or chimeric antigen receptor T cells) * Cyclophosphamide (a lymphodepleting chemotherapy) * Fludarabine (a lymphodepleting chemotherapy) Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies is being studied. Conditions: Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM) +3 • Eligibility: Inclusion Criteria 1. Voluntary participation with signed informed consent. 2. Pathologically confirmed CD19-positive and/or B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but…. Goal: This single-arm, dose-escalation exploratory trial evaluates the safety and efficacy of Allogeneic CAR-T (UCAR-T) cell therapy in patients with relapsed or refractory CD19+/BCMA+ hematologic malignancies, including those with minimal residual disease (MRD). Eligible patients will receive lymphodepletion followed by a single infusion of UCAR-T cells, either post-transplant or without transplantation depending on disease status. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; The First Affiliated Hospital with Nanjing Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether adding oral cyclophosphamide to carfilzomib and dexamethasone improves outcomes for adults with relapsed or refractory multiple myeloma who have previously received lenalidomide-based therapy. It aims to evaluate the safety and effectiveness of this combination in RRMM patients. Eligible participants are adults (19+), with measurable disease, good performance status, and prior therapy including lenalidomide; key exclusions include prior exposure to carfilzomib or cyclophosphamide, certain serious heart conditions, active other cancers in the last 5 years, and pregnancy. The study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have NRAS mutation in…. Goal: This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation. Binimetinib blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth when an NRAS mutation is present. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have an AKT mutation…. Goal: This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have a PIK3CA mutation…. Goal: This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma +2 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol * Patients must fulfill all…. Goal: This phase II MATCH treatment trial tests how well larotrectinib (LOXO-101) works in treating patients with cancer that has certain genetic changes. Larotrectinib (LOXO-101) is used in patients whose cancer has a mutated (changed) form of a gene called NTRK. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol * Patients must fulfill all…. Goal: This phase II MATCH treatment trial tests how well GDC-0449 (vismodegib) works for treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that does not respond to treatment (refractory) and who have a smoothened or patched 1 genetic mutation. Vismodegib is a type of medication called a hedgehog signaling pathway antagonist and works by blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether itacitinib, an immune-suppressing anti-inflammatory drug, given around a non‑myeloablative haploidentical peripheral blood stem cell transplant with high-dose posttransplant cyclophosphamide, can help older patients. - Researchers want to know if itacitinib can prevent severe cytokine release syndrome after transplant, reduce graft-versus-host disease, and possibly shorten the time patients need other immune-suppressing drugs. - Participants are people aged 60 and older with certain blood cancers who have a related, partially matched donor. - Key exclusions include active CNS leukemia, HIV, active HBV or HCV requiring treatment, pregnancy, and prior/allogeneic transplant or uncontrolled infection.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) is being studied. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3 • Eligibility: Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patient's tumor must have activating HER2…. Goal: This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations. Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health is being studied. Conditions: Breast Cancer, Colorectal Cancer, Endometrial Cancer +6 • Eligibility: Inclusion Criteria: * Age 50 years or older * Resident of the continental United States * Diagnosed with multiple myeloma, non-Hodgkin lymphoma, or localized kidney or ovarian cancer;…. Goal: This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Alabama at Birmingham.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests selinexor plus daratumumab, lenalidomide, and dexamethasone (S-DRd) as first-line treatment for adults with newly diagnosed multiple myeloma. - It is a single-arm, phase II, open-label trial to evaluate how well this combination works and its safety in this setting. - Eligible participants are adults (18+) with measurable, newly diagnosed MM, generally transplant-ineligible or not planning transplant for at least 24 months. - Key exclusions include active central nervous system involvement, HIV or hepatitis B/C infection, significant heart disease or QT prolongation, severe cytopenias or organ dysfunction, and pregnancy. - The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a human-derived anti-BCMA CAR-T cell therapy in people with relapsed or refractory multiple myeloma to assess safety, tolerability, and how the treatment behaves in the body, plus early signs of efficacy. It is a single-arm, open-label, dose-escalation study, so all participants receive the therapy and the dose is increased in steps to find a safe range. Eligible participants are adults aged 18–75 with multiple myeloma that has relapsed after or is refractory to at least three prior treatments, and who meet certain organ-function criteria; key exclusions include active infections, positive hepatitis B/C/HIV status, pregnancy or planned pregnancy, prior CAR-T or gene therapy, and other uncontrolled diseases or malignancies. The study will monitor adverse events, pharmacokinetic/pharmacodynamic characteristics, and preliminary efficacy after the infusion of BCMA CAR-T cells.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests whether four cycles of Carfilzomib-Revlimid-Dexamethasone (KRd) can help myeloma patients who are PET-positive after standard first-line treatment. - All eligible patients will have a PET-CT after first-line therapy, and only those who remain PET-positive will receive KRd; MRD in bone marrow and a new PET-CT will measure outcomes after treatment. - Participants should be adults with multiple myeloma who had standard first-line treatment with at least partial response or VGPR, are carfilzomib-naïve, and have adequate blood counts and performance status. - Key exclusions include progression on first-line therapy, CNS involvement, uncontrolled heart disease or severe HTN/diabetes, active hepatitis B/C or HIV, or another active cancer; the study is sponsored by Oslo University Hospital and is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests selinexor-based three-drug combinations in adults with relapsed or refractory multiple myeloma (RRMM). - Participants are assigned by their doctors to one of three regimens: selinexor with pomalidomide and dexamethasone (SPd), selinexor with daratumumab and dexamethasone (SDd), or selinexor with carfilzomib and dexamethasone (SKd). - Before treatment, patients undergo a bone marrow test and an ex vivo drug sensitivity test (My-DST) to study test performance, but results won’t guide assignment. - The study aims to see if this physician-driven selinexor-based approach can achieve an overall response rate of 75% or higher. - Key exclusions include prior selinexor exposure, uncontrolled infections or cardiovascular conditions, pregnancy, or recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia is being studied. Conditions: Diffuse Large B Cell Lymphoma, Multiple Myeloma • Eligibility: Inclusion Criteria: * Able to understand the purpose and risks of the study and to provide signed and dated informed consent and authorization to use confidential health information…. Goal: Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Leuko Labs, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial is being studied. Conditions: Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma +3 • Eligibility: Inclusion Criteria: * Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug. * Male subject…. Goal: The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tissue Microarray of Hematological Malignancies is being studied. Conditions: Hematological Malignancies • Eligibility: Inclusion Criteria: * hematological malignancy/neoplasm Exclusion Criteria: * Non-sufficient data available. Goal: The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests belantamab mafodotin with bortezomib and dexamethasone versus daratumumab with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. - It is a Phase 3, randomized, open-label study designed to compare safety and efficacy between the two regimens. - Participants are adults with at least one prior therapy and disease progression, plus measurable disease and adequate health status. - Key exclusions include intolerance or refractoriness to daratumumab or anti-CD38 therapy, intolerance or refractoriness to bortezomib, corneal epithelial disease, prior anti-BCMA therapy, or prior allogeneic stem cell transplant.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a Phase II, multicenter, open-label trial testing I-KRd (Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone) given as induction, consolidation, and maintenance for newly diagnosed high-risk multiple myeloma. - It targets adults with newly diagnosed, symptomatic, measurable myeloma who have high-risk features by specific cytogenetic abnormalities or ISS stage II/III. - The study aims to learn whether this regimen is safe and feasible and how well it controls the disease across the induction, consolidation, and maintenance phases. - Key exclusions include severe organ dysfunction, active infections, certain serious heart conditions, HIV/HBV/HCV infection, recent or ongoing other anti-myeloma therapy (with limited exceptions), and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is an open-label phase II trial testing isatuximab plus dexamethasone given around an autologous stem cell transplant for adults with relapsed multiple myeloma. Participants will first receive cytoreduction therapy to achieve at least partial remission, then have a melphalan-conditioned autologous stem cell transplant, followed by maintenance with isatuximab-dexamethasone for 12 cycles and then isatuximab alone until progression or intolerance. The study aims to learn whether this isatuximab-dexamethasone approach is effective and safe in the post-transplant setting. Eligible participants are adults 18–70 who have had an autologous transplant with relapse after at least 24 months and have adequate stem cell collection (at least 2.0 million CD34+ cells per kg). Key exclusions include prior anti-CD38 therapy, active HIV or hepatitis infections, active infections, CNS involvement by myeloma, and certain significant cardiac or other medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial is testing a dual-target CAR-T cell therapy that targets CD38 and CS1 in people with multiple myeloma. - It is for adults and older teenagers with relapsed or refractory multiple myeloma who have not achieved complete remission after standard treatment, generally ages 15 to 75 with adequate health status. - Researchers want to learn how well these CAR-T cells can kill myeloma cells that express CD38, CS1, or both, and how durable that effect is. - Key exclusions include active infections, HIV, HBV or HCV, pregnancy, and other uncontrolled illnesses. - The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Changing Over Time of Ascorbic Acid After Chemotherapy is being studied. Conditions: Leukemia (Both ALL and AML), Cancer of Lung, Myeloma • Eligibility: Inclusion Criteria: * 18 years or older * written informed consent * Require chemotherapy and will start this treatment in less than 1 month after registration for any…. Goal: Rationale: Recent studies showed that ascorbic acid (AA) stimulates proliferation and maturation of T lymphocytes and NK cells. Chemotherapy results in depletion of those cells and thereby an increased infection rate. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Maastricht University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation is being studied. Conditions: Multiple Myeloma, Hodgkin's Disease, Non-Hodgkin's Lymphoma • Eligibility: Inclusion Criteria: * Voluntary written informed consent * Subjects with Multiple Myeloma (MM), Hodgkin's Disease (HD), and non-Hodgkins lymphoma (NHL) who are eligible for high-dose chemotherapy and autologous…. Goal: By doing this study, researchers hope to learn the following: * The safety of hyperbaric oxygen administration in the setting of the autologous transplant * The effects of hyperbaric oxygen administration on neutrophil count recovery and engraftment Phase/Status/Sponsor: Unknown phase; UNKNOWN; University of Kansas Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies is being studied. Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum +4 • Eligibility: Inclusion Criteria: 1. Signed and dated informed consent 2. Male and Females age 18 to 80 years old at the time of screening 3. Confirmed tissue diagnosis of…. Goal: A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI Malignancies Phase/Status/Sponsor: Unknown phase; UNKNOWN; Leaf Vertical Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Role of CX3CR1-expressing Cells in Hematologic Malignancy is being studied. Conditions: CX3CR1 Protein, Diffuse Large B Cell Lymphoma, Multiple Myeloma • Eligibility: Inclusion Criteria: * Subject newly diagnosed multiple myeloma. * Subject newly diagnosed diffuse large B cell lymphoma. Exclusion Criteria: * History of other hematologic malignancy * History of…. Goal: This study evaluates the clinical significance of CX3CR1-expressing myeloid and lymphoid cells in patients of hematologic malignancy. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis and lymphopoiesis. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Saint Vincent's Hospital, Korea.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

In Vitro Drug Sensitivity Testing of Fresh Human Samples is being studied. Conditions: Myeloproliferative Disorders, Lymphoproliferative Disorders • Eligibility: Inclusion Criteria: * Index cases: patients with myeloproliferative or lymphoproliferative disorders. * Controls: patients without hematological disease, without chemotherapy ((≤ 5 years.) and without immunosuppressive treatment at the…. Goal: Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)) . Over the last decade, the treatments have evolved significantly but the overall survival remains limited, especially for the AML and MM patients. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Hospices Civils de Lyon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma is being studied. Conditions: Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma • Eligibility: Inclusion Criteria: 1. Active multiple myeloma in accordance with IMWG criteria，or histopathologically and immunohistochemically confirmed non-Hodgkin's lymphoma in accordance with the 2016 WHO Classification of lymphoid neoplasias. 2.…. Goal: This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Jiangsu HengRui Medicine Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion is being studied. Conditions: Multiple Myeloma • Eligibility: Inclusion Criteria: 1. Patients who have a new diagnosis of MM according to the International Myeloma Working Group (IMWG) working criteria undergoing autologous or syngeneic hematopoietic transplantation According…. Goal: The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population. The risk of such a study is deemed reasonable and ethical since: a) previous works have closely examined the safety and toxicity of the BEAM regimen and the doses to be delivered in this protocol are well below the toxicity levels; b) phase III trials of BEAM have provided reasonable data regarding the efficacy in lymphomas c) Early, retrospective data suggests that BEAM may be efficacious in MM however due to the lack of prospective controlled randomized clinical trial, there is adequate equipoise regarding its efficacy and moreover its comparative efficacy in relation to Melphalan and; D) there are known limitations in the standard-of-care for MM, Melphalan, namely, relatively low rates of complete response at the time of Autologous stem-cell transplantation (ASCT) and poor progression free survival. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Swedish Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Financial Difficulty in Patients With Blood Cancer is being studied. Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma • Eligibility: Inclusion Criteria: PATIENT ELIGIBILITY CRITERIA * Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) * Patients' medical records must be available to…. Goal: This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250) (Appendix A), a physician survey (n=100) (Appendix B), and a practice survey completed by each site enrolling patients onto this study (Appendix C). Phase/Status/Sponsor: Unknown phase; COMPLETED; UNC Lineberger Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies is being studied. Conditions: Hematological Malignancies, Leukemia, Lymphoma +2 • Eligibility: Inclusion Criteria: 1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been…. Goal: This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sidney Kimmel Cancer Center at Thomas Jefferson University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Oncology Outcomes Associated with Testing and Treatment is being studied. Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer +73 • Eligibility: Inclusion Criteria: * Patient or representative provides written informed consent * Patient is diagnosed with advanced malignancy * Patient is willing to be treated for this malignancy according…. Goal: This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Taproot Health.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma is being studied. Conditions: Multiple Myeloma • Eligibility: Accepts Healthy Volunteers: No Inclusion Criteria: 1. Subjects with a confirmed diagnosis of Multiple Myeloma who have had one and no more than three prior regimens for MM…. Goal: The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM). The primary objectives: * To establish the safety, tolerability, and recommended Phase II dose (RP2D) of KW-2478 in combination with bortezomib (Phase I); * To assess the overall response rate (ORR) when subjects with advanced MM are treated (Phase II). Phase/Status/Sponsor: Unknown phase; COMPLETED; Kyowa Kirin Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology is being studied. Conditions: Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies +2 • Eligibility: Inclusion Criteria: * Patients of more than 18 years of age * Patients presenting with anemia following chemotherapy * Patients suffer from solid tumours, malignant hemopathies, lymphomas or…. Goal: The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hospira, now a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of the Success of Prophylactic Enteral Nutrition in Therapeutic Intensification With Autograft of Autologous Hematopoietic Cells in Hematology is being studied. Conditions: Lymphoma, Myeloma • Eligibility: Inclusion Criteria: * Patient with lymphoma or myeloma * Patient admitted for therapeutic intensification with autologous hematopoietic cells who are eligible for nutritional support by enteral nutrition *…. Goal: When the digestive tract is functional, learned societies recommend the use of a nutritional support by enteral feeding. Indeed, it has many advantages (maintenance of gut trophicity, reduction of the risk of infection by reducing the incidence of bacterial translocations,...). Phase/Status/Sponsor: Unknown phase; COMPLETED; University Hospital, Bordeaux.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal) is being studied. Conditions: Relapse and/or Refractory Multiple Myeloma • Eligibility: Inclusion Criteria: 1. At least one previous treatment line. 2. Symptomatic R/R disease in the previous 6 months to study enrolment. 3. Receiving treatment with an accurate and…. Goal: The main aim of this study is to see how people with MM respond to previous or current treatment. Participants will be treated according to their clinic's standard practice. Phase/Status/Sponsor: Unknown phase; COMPLETED; Takeda.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies is being studied. Conditions: Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia +8 • Eligibility: Inclusion Criteria: * Patients with the following diseases: * Acute myeloid or lymphocytic leukemia in first remission at standard or high-risk for recurrence. * Acute leukemia in greater…. Goal: New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic activity with alkylating agents. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +4 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of a hematologic malignancy of 1 of the following high-risk types: * Acute lymphoblastic leukemia * Acute myeloid leukemia * Chronic myelogenous leukemia *…. Goal: RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 is being studied. Conditions: Advanced Malignancies • Eligibility: Inclusion Criteria: Among other criteria, patients must meet all of the following conditions to be eligible to be in the study: 1. 18 years of age or older.…. Goal: The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein. Phase/Status/Sponsor: Unknown phase; COMPLETED; Celldex Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pyroxamide in Treating Patients With Advanced Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +5 • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor or hematologic malignancy * Disease that has failed standard therapies (e.g., surgery, radiotherapy, endocrine therapy, or chemotherapy) or for…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +4 • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed malignancy Malignant lymphoma - Non-Hodgkin's lymphoma Intermediate and high grade (aggressive) histology with primary refractory disease or relapsed following standard therapy - Hodgkin's disease…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cancer Treatment Centers of America.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tipifarnib in Treating Patients With Advanced Hematologic Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +2 • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed hematologic malignancy refractory to standard therapy or for which no known effective therapy exists * Hodgkin's or non-Hodgkin's lymphoma * Known…. Goal: Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy * Tumor types may include any of the following: * Any solid tumor including,…. Goal: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparing Treatments for Multiple Myeloma is being studied. Conditions: Multiple Myeloma • Eligibility: INCLUSION CRITERIA Age 70 or younger at time of pretransplant evaluation. An established diagnosis of multiple myeloma. ECOG performance status of 0 or 1 and a life-expectancy of…. Goal: Some drugs have the ability to push stem cells (the cells responsible for producing new cell types) out of the bone marrow and into the blood stream. The steps involved in this process are still poorly understood. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Heart, Lung, and Blood Institute (NHLBI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ixazomib Rollover Study is being studied. Conditions: Multiple Myeloma, Lymphoma, Amyloidosis • Eligibility: Inclusion Criteria: 1. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care. Participants should consent and enter the study…. Goal: The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study. Phase/Status/Sponsor: Unknown phase; COMPLETED; Takeda.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Patient Reported Outcomes and Patient Education in Cellular Therapy Patients is being studied. Conditions: Stem Cell Transplant, CAR T-Cell Transplant, CAR T-Cell Therapy +6 • Eligibility: Inclusion Criteria: * Any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T)…. Goal: The purpose of this research is to provide an educational visit addressing common emotional stressors involved in the transplant/CAR-T process, and determine if this added education improves levels of anxiety, depression, and fatigue after transplant/CART in comparison to people who do not receive the brief educational visit. Phase/Status/Sponsor: Unknown phase; COMPLETED; Dartmouth-Hitchcock Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery is being studied. Conditions: Myelodysplastic Syndrome, Effects of Chemotherapy, Mild Cognitive Impairment +6 • Eligibility: Inclusion criteria: * HM diagnosis * scheduled to receive treatment based on risk classification * between 19 to 80 years of age- * normal or corrected-to-normal vision *…. Goal: Broadly speaking, the goal of this study is to better understand the influence of chemotherapy treatment on the cognitive and neural mechanisms underlying human behavior. Extant literature lacks diversity in studied cancer populations and treatment protocols, and provides limited understanding of the cognitive abilities that are impaired by chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Nebraska.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies is being studied. Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) +97 • Eligibility: Inclusion Criteria: * Patients must be not eligible for conventional transplants and must have disease expected to be stable for at least 100 days without chemotherapy; patients with…. Goal: This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in treating patients with hematological malignancies. Giving chemotherapy and low-dose TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma is being studied. Conditions: Malignant Lymphoma, Stem Cell Type, Autologous Transplant • Eligibility: Inclusion Criteria: * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by…. Goal: The purpose of this study is to determine if the combination of G-CSF and bortezomib is safe and effective in blood cell mobilization. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Kansas Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma is being studied. Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7) +70 • Eligibility: Criteria * Acute non-lymphocytic leukemia (FAB types M1-M7) in first, or second remission, or early first or second bone or marrow relapse (\>31% marrow blasts and no circulating…. Goal: RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests an oral drug called LP-118 in adults whose blood cancers have relapsed or are refractory, and it plans to enroll up to 100 participants. It is a Phase 1 study with dose-escalation (Phase 1a) and expansion (Phase 1b) to assess safety, tolerability, and how the drug behaves in the body. It aims to find the maximum tolerated dose or the recommended dose for future studies and to gather early signs of activity across several relapsed/refractory blood cancers, including CLL/SLL, AML, NHL, MM, and ALL. Key exclusions include recent stem cell transplant or active GVHD, uncontrolled infections, significant heart problems or QT prolongation, pregnancy, and the inability to take oral medication. The study is sponsored by Newave Pharmaceutical Inc and is currently recruiting at multiple centers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies is being studied. Conditions: Hematologic Malignancy • Eligibility: Major Inclusion Criteria: 1. Signed written informed consent must be obtained and documented according to the International Conference on Harmonisation (ICH) and be in accordance with local regulatory…. Goal: This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sumitomo Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor is being studied. Conditions: Febrile Neutropenia, Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Male or female adults (age \> / = 18 years) * Diagnosed with one of the following types and stages of tumors: stage III or…. Goal: This international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are receiving filgrastim biosimilar (EP2006) for primary or secondary FN prophylaxis to better describe the patient population at risk for FN and treated prophylactically in physician's best clinical judgement with filgrastim biosimilar (EP2006), to describe prophylaxis patterns involving filgrastim biosimilar (EP2006), and to evaluate hematology levels and variability in hematological outcomes, impact on chemotherapy delivery, radiotherapy, surgery, and mortality. Additionally the study aims to identify patient cohorts who are vulnerable to poor response to FN prophylaxis and experience break-through episodes of FN, understand the differences between prophylaxis responders and non-responders, and describe the degree to which prophylaxis of FN is in congruence with guideline recommendations. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sandoz.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization is being studied. Conditions: Multiple Myeloma, Lymphoma • Eligibility: Inclusion Criteria: 1. Participants must be 18 years of age or older 2. Patients must be able to provide written consent 3. Participants must have a diagnosis of…. Goal: Poor mobilization of hematopoietic progenitors needed to support autologous transplantation is a serious clinical problem. We are investigating the role of plerixafor administered in an at risk population to augment successful stem cell collection. Phase/Status/Sponsor: Unknown phase; COMPLETED; CancerCare Manitoba.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Blood Samples From Patients on a Clinical Trial to CINV During HSCT is being studied. Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor +9 • Eligibility: DISEASE CHARACTERISTICS: * Previously collected serum samples from patients with cancer enrolled on the placebo arm of the pilot aprepitant study * Patients treated with busulfan/cyclophosphamide or cyclophosphamide/total…. Goal: RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment. PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant. Phase/Status/Sponsor: Unknown phase; TERMINATED; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation is being studied. Conditions: Leukemia, Lymphoma, Hodgkin's Disease +3 • Eligibility: Inclusion Criteria: One of these diagnoses: * Acute myeloid leukemia in complete or partial remission * Acute lymphocytic leukemia in complete or partial remission * Chronic myeloid leukemia…. Goal: This study tests the hypothesis that a purely immunosuppressive preparative regimen allows engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with high-risk malignancies, without causing the post-transplant myelosuppression (e.g., neutropenia, thrombocytopenia) that occurs with currently used reduced-intensity (nonmyeloablative) preparative regimens. This study incorporates both safety and efficacy endpoints and evaluates a novel preparative regimen of alemtuzumab plus continuous-infusion pentostatin, two immunosuppressive agents with different mechanisms of action, in recipients of related or unrelated allogeneic hematopoietic stem cell transplantation. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia +4 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following hematologic malignancies: * Acute myeloid leukemia (AML) with or without history of myelodysplastic syndromes, meeting 1 of the following…. Goal: RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Rochester.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy is being studied. Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia +4 • Eligibility: Inclusion Criteria: 1. Relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), high risk myelodysplasia (MDS) with an IPSS score \> 2.5,…. Goal: This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies. The study will also characterize Cliquinol's safety, tolerability and pharmacodynamic effect. Phase/Status/Sponsor: Unknown phase; TERMINATED; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain is being studied. Conditions: Tumor, Cancer, Pain +6 • Eligibility: Inclusion Criteria: * Patients must have metastatic or unresectable solid malignancy or hematologic malignancy (multiple myeloma or lymphoma) and must have moderate to severe tumor related pain visual…. Goal: The purpose of this study is to: * Determine how well people tolerate sodium bicarbonate taken by mouth in higher doses than those usually given for heartburn. * Determine if sodium bicarbonate can reduce cancer-related pain. Phase/Status/Sponsor: Unknown phase; TERMINATED; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant is being studied. Conditions: Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia +6 • Eligibility: DISEASE CHARACTERISTICS: * Disease in remission * More than 365 days since prior allogeneic hematopoietic stem cell transplantation with history of full donor engraftment * Stable complete donor…. Goal: RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase I research study is looking at the presence of donor-derived DNA in semen samples form cancer survivors who underwent donor stem cell transplant. Phase/Status/Sponsor: Unknown phase; TERMINATED; Vanderbilt University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers is being studied. Conditions: Multiple Myeloma, Neoplasms • Eligibility: Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Must have recovered from all side effects of their most recent systemic or local treatment…. Goal: This open-label, multi-center study will assess the efficacy and safety of vemurafenib in participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinion of the investigator. Participants will receive twice daily oral doses of 960 mg vemurafenib until disease progression, unacceptable toxicity, or withdrawal of consent. Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies is being studied. Conditions: Lymphoma, Breast Neoplasms, Lung Neoplasms +2 • Eligibility: * Patients with non-myeloid malignancies \* Patients receiving at least 12 weeks of chemotherapy on a 3-week cycle schedule \* Patients with anemia (hgb \>/= 9.0 and \</=…. Goal: Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Amgen.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies is being studied. Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia +3 • Eligibility: Inclusion Criteria: * Recipients of first ASCT from related or unrelated donor for the treatment of hematologic malignancies (acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic…. Goal: This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; Barbara Ann Karmanos Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.